Company profile
PHATHOM PHARMACEUTICALS, INC.
NASDAQ:PHATBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VOQUEZNA | approved | $58.3MQ1 2026 | 26 | approved |
| VOQUEZNA DUAL PAK | approved | — | 38 | approved |
| VOQUEZNA TRIPLE PAK | approved | — | 43 | approved |
| VONOPRAZAN FUMARATE | phase3 | — | 26 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06851559 | phase2 | active_not_recruiting | 2025-10-30 | 2026-10-01 | Phathom Pharmaceuticals, Inc. | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks |
| NCT05366738 | phase1 | completed | 2022-05-18 | 2022-07-01 | Phathom Pharmaceuticals, Inc. | A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants |
| NCT06831344 | phase1 | completed | 2025-02-14 | 2025-04-05 | Phathom Pharmaceuticals, Inc. | A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants |
| NCT06391177 | phase1 | completed | 2024-05-07 | 2024-09-13 | Phathom Pharmaceuticals, Inc. | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily |
| NCT06106022 | phase1 | completed | 2023-11-01 | 2024-04-16 | Phathom Pharmaceuticals, Inc. | A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease |
FDA applications (4)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 215151 | 2023-11-01 | NDA | PHATHOM PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 215152 | 2022-05-03 | NDA | PHATHOM PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 215153 | 2022-05-03 | NDA | PHATHOM PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 218710 | — | NDA | PHATHOM PHARMACEUTICALS INC | |||||
Loading… | ||||||||